Next Article in Journal
Outcome Prediction of Acute Kidney Injury Biomarkers at Initiation of Dialysis in Critical Units
Next Article in Special Issue
Proteases and Their Inhibitors in Chronic Obstructive Pulmonary Disease
Previous Article in Journal
Bullying at Workplace and Brain-Imaging Correlates
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessFeature PaperReview
J. Clin. Med. 2018, 7(8), 201; https://doi.org/10.3390/jcm7080201

Idiopathic Pulmonary Fibrosis (IPF): An Overview

1
Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Bristol BS10 5NB, UK
2
Academic Respiratory Unit, University of Bristol, Bristol BS16 1QY, UK
3
North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, Wythenshawe, Manchester M23 9LT, UK
*
Author to whom correspondence should be addressed.
Received: 27 June 2018 / Revised: 23 July 2018 / Accepted: 31 July 2018 / Published: 6 August 2018
Full-Text   |   PDF [1093 KB, uploaded 6 August 2018]   |  

Abstract

Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic, progressive scarring of the lungs and the pathological hallmark of usual interstitial pneumonia. Current paradigms suggest alveolar epithelial cell damage is a key initiating factor. Globally, incidence of the disease is rising, with associated high morbidity, mortality, and economic healthcare burden. Diagnosis relies on a multidisciplinary team approach with exclusion of other causes of interstitial lung disease. Over recent years, two novel antifibrotic therapies, pirfenidone and nintedanib, have been developed, providing treatment options for many patients with IPF, with several other agents in early clinical trials. Current efforts are directed at identifying key biomarkers that may direct more customized patient-centred healthcare to improve outcomes for these patients in the future. View Full-Text
Keywords: idiopathic pulmonary fibrosis; interstitial lung disease; nintedanib; pirfenidone idiopathic pulmonary fibrosis; interstitial lung disease; nintedanib; pirfenidone
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Barratt, S.L.; Creamer, A.; Hayton, C.; Chaudhuri, N. Idiopathic Pulmonary Fibrosis (IPF): An Overview. J. Clin. Med. 2018, 7, 201.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top